Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.

Increases in growth velocity were highly significant for participants with a baseline growth velocity <5 cm/year (n = 14, p < 0.0001) but were not significant for those whose baseline growth velocity was above this cut-off (n = 10, p = 0.13).

also in 132,142 other papers